| Similar Articles |
|---|
 |
The Motley Fool
December 6, 2011
Rex Moore |
Screening for Winning Stocks Here's a state-of-the-portfolio address, one year into my real-money, Rising Stars fun.   |
The Motley Fool
May 27, 2011
Rex Moore |
Rising Star Buys: More Tech and Health Care Making the halves whole with II-VI, J&J, and Abbott. |
The Motley Fool
February 25, 2011
Rex Moore |
Rising Star Buys: 2 Health Care Winners Abbott Laboratories and Johnson & Johnson are being added to the Motley Fool multivitamin portfolio. |
The Motley Fool
April 12, 2011
Rex Moore |
Best Stocks for the Long Haul You need some corporate El Dorado stocks in your portfolio. Here's where to start searching for them. |
The Motley Fool
February 25, 2010
Rex Moore |
The Most Compelling Case Yet for These Stocks Increasing your exposure to foreign stocks, up to a certain point, both raises your expected returns and lowers your risk. |
The Motley Fool
February 24, 2009
Brian Orelli |
Pfizer: Diversified Dreams, Dubious Decisions Pfizer's CEO Jeffrey Kindler said he wants to make his company more like Johnson & Johnson and Abbott Labs, which aren't dependent on one product for success. |
The Motley Fool
October 20, 2011
Brian Orelli |
Mini J&J? I Guess Not Abbott says it plans to split in two: drugs in one company, everything else in the other. |
The Motley Fool
July 14, 2008
Brian Orelli |
Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut? |
The Motley Fool
March 29, 2010
Rex Moore |
The Most Compelling Case Yet for These Stocks It's the closest thing there is to a free lunch. Increasing your exposure to foreign stocks, up to a certain point, both raises your expected returns and lowers your risk |
The Motley Fool
July 19, 2011
Brian Orelli |
J&J: Better, but Not Best A decent-looking quarter, but a turnaround could still take awhile. |
The Motley Fool
February 24, 2011
Brian Orelli |
Abbott: 1, Johnson & Johnson: 0 -- For Now Abbott Labs got a ruling overturned yesterday that would have cost the company $1.8 billion, yet investors let shares slip down 1%. |
The Motley Fool
August 24, 2010
Brian Orelli |
One Day, the J&J Recalls Will End Just not today. Johnson & Johnson's consumer health segment gets more than half of its sales from outside the U.S., so tainting its image outside the U.S. could be costly as well. |
The Motley Fool
January 18, 2011
Russ Krull |
Keep It or Sweep It: Johnson & Johnson? Should the company be held or sold? |
The Motley Fool
January 26, 2010
Brian Orelli |
Is the Best of Johnson & Johnson Behind It? Johnson & Johnson announces that its sales fell for the first time in 76 years. |
The Motley Fool
January 10, 2012
Rex Moore |
January's Best Stocks for the Long Haul You need some corporate El Dorados in your portfolio. Here's where to find them. |
The Motley Fool
July 12, 2010
Brian Orelli |
Johnson & Johnson MENDs a Hole Another neurovascular device maker, Micrus Endovascular, gets snatched up. |
The Motley Fool
December 10, 2010
Rex Moore |
Screening for Great Small Caps Here are the candidates for our next buy. |
The Motley Fool
December 30, 2010
Rex Moore |
5 Small Caps to Juice Your Portfolio These are the five solid candidates for the Motley Fool Rising Star Portfolio small cap buys: lululemon athletica... Ebix... MercadoLibre... Puda Coal... ZAGG... |
The Motley Fool
July 17, 2008
Brian Orelli |
Investors Yawn at Abbott Labs' Growth Abbott Labs may be firing on all cylinders, but investors were less than impressed with its earnings release |
The Motley Fool
October 28, 2010
Matt Koppenheffer |
Blue Chips Are Crazy Cheap Blue chip stocks are where investors should be focusing, and there's good reason why. |
The Motley Fool
January 27, 2010
Brian Orelli |
Humira or Not, Abbott's on a Roll Investors worry about how Abbott's Humira is such a large fraction of the company's revenue, and then when the company turns in a nice quarter even without strong U.S. sales of Humira, they complain about that. |
The Motley Fool
May 20, 2009
Brian Orelli |
Johnson & Johnson Tries to Pull a Travolta Johnson & Johnson seems to be making a comeback, after its drug-eluting stent market share fell precipitously to just 15% in the first quarter. |
The Motley Fool
February 25, 2011
Matt Koppenheffer |
Everybody Loves Large-Cap Stocks Everyone seems to talk the talk when it comes to large caps. So how come nobody's buying? |
The Motley Fool
June 15, 2011
Brian Orelli |
Johnson & Johnson Is a Quitter The diversified health-care giant has decided to exit the drug-eluting stent market. |
The Motley Fool
March 4, 2008
Todd Wenning |
Stocks Worth Searching For These gems aren't easy to find, but they're worth the struggle. |
The Motley Fool
February 19, 2011
Rex Moore |
5 Rising Star Candidates These "Mod-8" stocks have great potential. |
The Motley Fool
November 26, 2010
Brian Orelli |
Get It Together, Johnson & Johnson Another day, another recall. |
The Motley Fool
August 27, 2010
Brian Orelli |
A Recall a Week, That's All We Ask For Johnson & Johnson, apparently that's too much. |
The Motley Fool
December 14, 2006
Rex Moore |
The Closest Thing to a Free Lunch Getting some international exposure in your portfolio may be one of the best things you can do as an investor. |
The Motley Fool
June 8, 2011
Rex Moore |
5 Stocks With Big Potential The search continues for some great small- and mid-cap stocks. These five may fit the bill: NetEase... lululemon... Ebix... iGATE... LSB Industries... |
The Motley Fool
January 22, 2009
Brian Orelli |
Abbott Labs Thumbs Nose at Recession On a GAAP basis, Abbott Labs fourth-quarter earnings per share were up a whopping 27%, and even better, the double-digit increases don't look like they're going to stop anytime soon. |
The Motley Fool
September 23, 2010
Brian Orelli |
This Recall Should Bug You Abbott Labs announces a recall of some types of its Similac baby formula because it found beetles and their larvae in an area of one of its plants. |
The Motley Fool
June 28, 2011
Eric Bleeker |
Johnson & Johnson Is Looking Abroad for Growth Where's Johnson & Johnson generating its sales? |
The Motley Fool
March 17, 2009
Brian Orelli |
Stent Wars, Episode III: The Rise of Xience V Johnson & Johnson lose the lead in the stent war race, but this is a marathon, not a footrace. |
The Motley Fool
January 20, 2009
Brian Orelli |
Johnson & Johnson Nimble ... for Now The health-care giant reports increasing earnings, despite falling revenue. |
The Motley Fool
September 5, 2008
Brian Orelli |
Zimmer Fortifies Its Spine The medical-device maker is buying Abbott's spine business. |
The Motley Fool
December 8, 2010
Rex Moore |
Building Out Your Best Portfolio My real-money portfolio picked up the "multivitamin" name because it can provide you with everything you need for stock portion of your overall financial picture. |
The Motley Fool
November 8, 2011
Brian Wilson |
2 Health-Care Stocks for Times of Uncertainty Just because Abbott and Johnson & Johnson don't undertake as much risk as other health-care giants doesn't mean that shareholders won't see impressive growth in revenues. |
The Motley Fool
June 4, 2010
Brian Orelli |
Out With Drugs, in With Medical Devices Johnson & Johnson's movement in medical devices and diagnostics is headed in the right direction, but whether Johnson & Johnson is a buy depends a lot on how it handles its current drug problem. Unfortunately investors can't have one without the other. |
The Motley Fool
September 22, 2009
Selena Maranjian |
33 Companies That Could Change the World Will a focus on sustainability pay off? |
The Motley Fool
September 30, 2009
Brian Orelli |
Boston Scientific Pays Up And Johnson & Johnson reaps the rewards. |
The Motley Fool
April 29, 2005
Bill Barker |
Using a Chimp to Improve Your Returns Jeremy Siegel's constant posits that annual real returns for the stock market over the long term will always be 6.5% to 7% per year. But there's a way for you to improve on that. |
The Motley Fool
January 3, 2011
Rex Moore |
Highest-Yielding Pharma Stocks (You Might Actually Want to Buy) How to combine high yield with low risk. |
The Motley Fool
December 12, 2011
Rex Moore |
December's Best Stocks for the Long Haul Dividend-paying stocks act as "bear-market protectors" and "return accelerators." Here's where to find them. |
The Motley Fool
January 26, 2011
Brian Orelli |
J&J Will Recover -- Someday Consumer health care might be the smallest of Johnson & Johnson's three divisions, but the 15% drop in revenue still hurts. A lot. |
The Motley Fool
June 16, 2010
Rick Steier |
A Lulu of a Stock, Even in a Recession When a secular trend supports a company concept, it can succeed in any economic climate. |
Financial Advisor
September 2009
Raymond Fazzi |
A Small Risk Conventional wisdom says small caps are riskier than their large-cap counterparts, but they remain a basic building block in retirement portfolios. |
The Motley Fool
January 23, 2008
Brian Orelli |
A Dose of Stability From J&J Top-line growth looked great at Johnson & Johnson -- more than 16% year over year -- but when you dove a little further into the earnings, growth wasn't quite that stellar. |
The Motley Fool
March 24, 2011
Anand Chokkavelu |
Rising Star Buy: Johnson & Johnson It's time to buy shares of Johnson & Johnson, the "health-care mutual fund." |
The Motley Fool
June 30, 2009
Brian Orelli |
Johnson & Johnson Inflames Abbott $1.67 billion is one hefty reward. |
